In vivo mucosal delivery of bioactive human interleukin I receptor antagonist produced by Streptococcus gordonii

BMC Biotechnology

Volumn 3, Issue , 2003, Pages

  Ricci, Sussana ^a   Macchia, Giovanni ^b,c   Ruggiero, Paolo ^b,d   Maggi, Tiziana ^a,d   Bossù, Paola ^e   Xu, Li ^f   Medaglini, Donata ^a   Tagliabue, Aldo ^g   Hammarström, Lennart ^f   Pozzi, Gianni ^a   Boraschi, Diana ^h  

^a UNIVERSITY OF SIENA   (Italy)

^b Chemistry Section   (Italy)

^c EUROPEAN PATENT OFFICE   (Netherlands)

^d CHIRON VACCINES   (Italy)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g International Vaccine Institute   (South Korea)

^h INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; ARGININE; HYBRID PROTEIN; INTERLEUKIN 2; M PROTEIN; PHENYLALANINE; PROBIOTIC AGENT; PROLINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VALINE;

AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BODY WEIGHT; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GASTROINTESTINAL MUCOSA; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; STREPTOCOCCUS GORDONII; ULCERATIVE COLITIS; VAGINA MUCOSA;

ANIMALIA; STREPTOCOCCUS; STREPTOCOCCUS GORDONII;

EID: 3042559646     PISSN: 14726750     EISSN: None     Source Type: Journal    
DOI: 10.1186/1472-6750-3-15     Document Type: Article

References (58)

1. Hedley ML: Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000, 44:195-207.
2. Holtmann MH, Galle PR and Neurath MF: Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 2001, 1:455-466.
3. Shanahan F: Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001, 120:622-635.
4. Schultz M and Sartor RB: Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000, 95:19-21.
5. Dinarello CA: Proinflammatory cytokines. Chest 2000, 118:503-508.
6. Arend WP, Malyak M, Guthridge CJ and Gabay C: Interleukin-1 receptor antagonist: role in biology. Ann Rev Immunol 1998, 16:27-55.
7. Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998, 16:457-499.
8. Mantovani A, Dinarello CA and Ghezzi P: Interleukin-1 receptor antagonist. In Pharmacology of cytokines Edited by: Mantovani A, Dinarello CA, Ghezzi P. Oxford: Oxford University Press; 2000:91-119.
9. Dinarello CA and Moldawer LL: Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primer for clinicians. Thousand Oaks: Amgen Inc 2001.
10. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R and Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348:550-552.
11. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC and Dinarello CA: A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991, 5:338-343.
12. Hirsch E, Irikura VM, Paul SM and Hirsh D: Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 1996, 93:11008-11013.
13. Giannoukakis N, Rudert WA, Ghivazzani SC, Gambotto A, Ricordi C, Trucco M and Robbins PD: Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1 beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999, 48:1730-1736.
14. Yang GY, Davidson BL and Betz AL: Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997, 751:181-188.
15. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, La Brecque JF, Catalano MA, Knaua WA and Sadoff JC: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994, 271:1836-1843.
16. Krishnan BR: Interleukin-1 receptor antagonist gene therapy for arthritis. Curr Opin Mol Ther 1999, 4:454-457.
17. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT and Wright TM: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996, 7:1261-1280.
18. Gabay C and Arend WP: Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol 1998, 20:229-246.
19. Rogler G and Andus T: Cytokines in inflammatory bowel disease. World J Surg 1998, 22:382-389.
20. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
21. Casini-Raggi V, Kam L, Chong YJT, Fiocchi C, Pizarro TT and Cominelli F: Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995, 154:2434-2440.
22. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC and Cominelli F: Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994, 94:449-453.
23. Dionne S, D'Agata ID, Hiscott J, Vanounou T and Seidman EG: Colonic explant production of IL-1 and its receptor antagonist is unbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998, 112:435-442.
24. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD and Duff GW: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994, 106:637-642.
25. Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI and Cominelli F: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999, 117:806-813.
26. Witkin SS, Gerber AS and Ledger WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002, 34:204-209.
27. Pozzi G, Oggioni MR and Medaglini D: Recombinant Streptococcus gordonii as live vehicle for vaccine antigens. In Gram-positive bacteria. Vaccine vehicles for mucosal immunization Edited by: Pozzi G, Wells JM. Springer-Verlag (Berlin) and Landes Bioscience (Georgetown, TX); 1997:35-60.
28. Ricci S, Medaglini D, Rush CM, Marcello A, Manganelli R, Palú G and Pozzi G: Immunogenicity of the B monomer of the Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. Infect Immun 2000, 68:760-766.
29. Beninati C, Oggioni MR, Boccanera M, Spinosa MR, Maggi T, Conti S, Magliani W, De Bernardis F, Teti G, Cassone A, Pozzi G and Polonelli L: Therapy of mucosal candidiasis by expression of an antiidiotype in human commensal bacteria. Nat Biotechnol 2000, 18:1060-1064.
30. Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella RS and Boyd MR: The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 2002, 16:1351-1356.
31. Oggioni MR and Pozzi G: A host-vector system for heterologous gene expression in Streptococcus gordonii. Gene 1996, 169:85-90.
32. Medaglini D, Oggioni MR, Contorni M, Cavalieri F and Pozzi G: Secretion of heterologous proteins in Streptococcus gordonii (Streptococcus sanguis) Challis. In DNA Transfer and Gene Expression in Microorganisms Edited by: Balla E, Berencsi G, Szentirmai A. Andover: Intercept Ltd; 1993:263-268.
33. Pozzi G, Musmanno RA, Lievens PMJ, Oggioni MR, Plevani P and Manganelli R: Methods and parameters for genetic transformation of Streptococcus sanguis Challis. Res Microbiol 1990, 141:659-670.
34. Medaglini D, Oggioni MR and Pozzi G: Vaginal immunization with recombinant Gram positive bacteria. Am J Reprod Immunol 1998, 39:199-208.
35. Sadlack B, Hartmut M, Schorle H, Schimpl A, Feller AC and Horak I: Ulcerative colitis-like disease in mice with disrupted interleukin-2 gene. Cell 1993, 75:253-261.
36. Horak I, Lohler J, Ma A and Smith KA: Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995, 148:35-44.
37. de Villiers WJ, Varilek GW, de Beer FC, Guo JT and Kindy MS: Increased serum amyloid A levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine 2000, 12:1337-1347.
38. Autenrieth IB, Bucheler N, Bohn E, Heinze G and Horak I: Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with inflammatory bowel disease. Gut 1997, 41:793-800.
39. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C and Pelletier J-P: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544.
40. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, Haskill JS and Schwab JH: Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996, 93:402-406.
41. Muller-Ladner U, Roberts CRFBN, Gay RE, Robbins PD, Evans CH and Gay S: Human IL-1ra gene transfer into human synovial fibroblast is chondroprotective. J Immunol 1997, 158:3492-3498.
42. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC and Martel-Pelletier J: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019.
43. Evans CH and Robbins PD: Potential treatment of osteoarthritis by gene therapy. Rheum Dis Clin North Am 1999, 25:333-344.
44. Steidler L, Robinson K, Chamberlain LM, Schofield KM, Remaut E, Le Page RWF and Wells JM: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 1998, 66:3183-3189.
45. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W and Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
46. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, Van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, Van Dollenweerd C, Ma JKC and Hammarstrom L: In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 2002, 20:702-706.
47. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, Saucedo-Cardenas O, Montes de Oca-Luna R and Le Loir Y: Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003, 71:1887-1896.
48. Takii T, Honda H, Sasayama S, Kobayashi T, Ikezawa H, Udaka S, Oomoto Y and Onozaki K: Human interleukin-1 receptor antagonist: large-scale expression in Bacillus brevis 47-5Q. J Interferon Citokine Res 1999, 19:1325-1331.
49. Zanette D, Dundon W, Soffientini A, Sottani C, Marinelli F, Akeson A and Sarubbi E: Human IL-1 receptor antagonist from Escherichia coli : large-scale microbial growth and protein purification. J Biotechnol 1998, 64:187-196.
50. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP and Remaut E: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003, 21:785-789.
51. Maggi T, Spinosa MR, Ricci S, Medaglini D, Pozzi G and Oggioni MR: Genetic engineering of Streptococcus gordonii for the simultaneous display of two heterologous proteins at the bacterial surface. FEMS Microbiol Lett 2002, 210:135-141.
52. Bossú P, Visconti U, Ruggiero P, Macchia G, Muda M, Bertini R, Bizzarri C, Colagrande A, Sabbatini V, Maurizi G, Del Grosso E, Tagliabue A and Boraschi D: Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol 1995, 147:1852-1861.
53. Boraschi D, Bossú P, Ruggiero P, Tagliabue A, Bertini R, Macchia G, Gasbarro G, Pellegrini L, Melillo G, Ulisse E, Visconti U, Bizzarri C, Del Grosso E, Mackay AR, Frascotti G, Frigerio F, Grifantini R and Grandi G: Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra like domains. J Immunol 1995, 155:4719-4725.
54. Stoppacciaro A, Bossú P, Ghiara P, Ruco LP, Censini S, Scapigliati G, Nuti S, Tagliabue A, Baroni CD and Boraschi D: Binding of IL-1 beta to IL-1R type II at single cell level. J Immunol 1991, 147:1561-1566.
55. Poole S and Gaines Das RE: The international standards for interleukin-1 alpha and interleukin-1 beta. Evaluation in an international collaborative study. J Immunol Methods 1991, 142:1-13.
56. Ruggiero P, Bossú P, Macchia G, Del Grosso E, Sabbatini V, Bertini R, Colagrande A, Bizzarri C, Maurizi G, Di Cioccio V, D'Andrea G, Di Giulio A, Frigerio F, Grifantini R, Grandi G, Tagliabue A and Boraschi D: Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II. J Immunol 1997, 158:3881-3887.
57. Medaglini D, Rush CM, Sestini P and Pozzi G: Commensal bacteria as vehicles for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci includes local and systemic antibodies in mice. Vaccine 1997, 15:1330-1337.
58. Schorle H, Holtschke T, Hunig T, Schimpl A and Horak I: Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352:621-624.